Last updated: October 8, 2026
RoxyBond is an abuse-deterrent immediate-release oxycodone hydrochloride tablet marketed in the United States by Collegium Pharmaceutical. The product received FDA approval in 2017 under NDA 209777. Its commercial position depends on a narrow segment of the oxycodone market: prescribers and payers seeking an FDA-labeled abuse-deterrent formulation rather than the lowest-cost immediate-release opioid.
RoxyBond has limited publicly disclosed product-level revenue. Collegium reports consolidated product revenue and discusses its commercial portfolio, but it does not separately disclose annual RoxyBond sales. The product’s financial contribution is therefore best assessed through prescription trends, payer access, opioid-market contraction, competitive positioning against generic oxycodone, and Collegium’s broader portfolio economics.
What is RoxyBond and how does its formulation differ from generic oxycodone?
RoxyBond contains oxycodone hydrochloride, an opioid agonist indicated for the management of pain severe enough to require an opioid analgesic when alternative treatments are inadequate. It is an immediate-release tablet available in 5 mg and 15 mg strengths. The product’s abuse-deterrent properties are intended to make manipulation for snorting or injection more difficult, although the formulation does not eliminate abuse, addiction, overdose, or diversion risks. [1]
RoxyBond uses an abuse-deterrent formulation developed by Inspirion Delivery Sciences. The FDA approved it under the Abuse-Deterrent Opioid Analgesics guidance and classified its labeling under the FDA’s abuse-deterrence framework. [2]
| Attribute |
RoxyBond |
| Active ingredient |
Oxycodone hydrochloride |
| Dosage form |
Immediate-release tablet |
| Strengths |
5 mg and 15 mg |
| FDA approval |
April 2017 |
| NDA |
209777 |
| Controlled-substance schedule |
Schedule II |
| Abuse-deterrent route |
Physical and chemical manipulation resistance |
| Primary commercial owner |
Collegium Pharmaceutical |
| Therapeutic category |
Opioid analgesic |
| Market position |
Branded abuse-deterrent immediate-release oxycodone |
Generic oxycodone immediate-release tablets generally compete on price but do not necessarily have the same abuse-deterrent formulation or labeling. This distinction limits direct automatic substitution in some payer and pharmacy settings, although prescribers may select non-abuse-deterrent oxycodone when cost is the dominant factor.
What is the FDA regulatory status of RoxyBond?
RoxyBond remains an FDA-approved Schedule II opioid product. Its approval is based on oxycodone’s analgesic efficacy and formulation-specific abuse-deterrence data. FDA approval does not establish that RoxyBond reduces overall opioid abuse or addiction in the population. The FDA label states that abuse-deterrent properties are expected to reduce manipulation by certain routes but cannot prevent abuse by other methods, including oral abuse. [1]
RoxyBond is subject to the FDA’s opioid Risk Evaluation and Mitigation Strategy, or REMS. The opioid analgesic REMS includes prescriber education, patient counseling, and safe-use requirements applicable across the opioid class. [3]
The FDA’s broader regulatory environment has become more restrictive since RoxyBond’s approval. Key market pressures include:
- Tighter opioid prescribing policies.
- State-level limits on initial opioid prescriptions.
- Prescription drug monitoring programs.
- Increased payer utilization controls.
- Public and private litigation against opioid manufacturers and distributors.
- Greater emphasis on non-opioid and non-pharmacologic pain treatment.
- Continued FDA scrutiny of opioid labeling and post-market safety.
These policies constrain market expansion even when a branded product offers abuse-deterrent technology.
How large is the RoxyBond market?
The addressable market for RoxyBond is the U.S. immediate-release oxycodone market, but its commercially reachable segment is smaller because most prescriptions remain price-sensitive and generic competition is extensive.
The U.S. opioid market has contracted from its peak in the early 2010s. CDC data show that opioid prescribing rates declined materially from 2012 through 2022, although prescribing remains substantial and varies by state, age group, specialty, and pain condition. [4]
RoxyBond competes in four overlapping segments:
- Generic immediate-release oxycodone.
- Branded immediate-release opioid products.
- Abuse-deterrent extended-release opioids.
- Non-opioid pain treatments and interventional therapies.
Its strongest commercial rationale is not broad opioid-market growth. It is product selection in institutional, government, or commercial formularies that give weight to abuse-deterrent technology, diversion controls, or opioid stewardship.
What limits RoxyBond demand?
The principal demand constraints are:
- Generic oxycodone price discounts.
- Declining opioid utilization.
- Restrictive payer policies.
- Limited willingness to pay for abuse-deterrent immediate-release products.
- Low physician awareness of formulation-specific differences.
- Reduced opioid prescribing in primary care.
- Substitution toward non-opioid analgesics.
- Hospital and health-system preference for standardized generic formularies.
Abuse-deterrent labeling can support formulary discussions, but it does not automatically produce a reimbursement premium. Payers often require prior authorization or step therapy before covering a branded opioid.
Who owns and markets RoxyBond?
Collegium Pharmaceutical is the principal commercial company associated with RoxyBond. Collegium built its portfolio around specialty pain medicines and controlled substances, including Xtampza ER, Nucynta, Belbuca, Symproic, and RoxyBond. The company’s strategy is to use a commercial infrastructure focused on pain management, controlled-substance compliance, and specialty pharmacy distribution. [5]
The product originated with Inspirion Delivery Sciences, which developed the abuse-deterrent technology. Collegium subsequently obtained commercial rights to RoxyBond. Public company disclosures have not provided a separate RoxyBond revenue line comparable with the company’s larger products.
The product’s economics therefore depend on:
- Collegium’s sales-force allocation.
- Contracting with pharmacy benefit managers.
- Government reimbursement.
- Wholesale acquisition cost and rebates.
- Distribution controls.
- The comparative value of abuse-deterrence claims.
- Collegium’s ability to maintain manufacturing and supply continuity.
What is the financial trajectory for RoxyBond?
RoxyBond’s standalone financial trajectory is not publicly quantifiable from Collegium’s reported segment disclosures. Collegium reports consolidated net product revenue and product-level performance for selected major products, but it does not publish a consistent annual RoxyBond revenue series.
The available financial conclusion is that RoxyBond is a portfolio product rather than a primary revenue engine. Collegium’s larger commercial drivers have been its extended-release and branded pain products, especially Xtampza ER and Nucynta. RoxyBond contributes to portfolio breadth but has limited disclosed impact on consolidated revenue, adjusted EBITDA, or valuation.
| Financial factor |
Effect on RoxyBond |
| Unit demand |
Constrained by declining opioid prescribing |
| Price |
Higher than generic oxycodone because of branded formulation and commercialization costs |
| Gross margin |
Potentially attractive if manufacturing volume is efficient |
| Reimbursement |
Vulnerable to prior authorization and non-preferred formulary status |
| Revenue visibility |
Low because Collegium does not separately disclose sales |
| Growth outlook |
More likely stable or declining than high growth |
| Strategic value |
Supports Collegium’s abuse-deterrent and pain portfolio |
| Valuation contribution |
Likely secondary to larger Collegium products |
RoxyBond could generate stable niche revenue if a payer, hospital system, or government program values abuse-deterrent labeling. A material acceleration would require broader formulary adoption, a policy preference for abuse-deterrent immediate-release opioids, or a decline in competing branded supply. None of those factors is established as a current base-case market trend.
What patents protect RoxyBond?
RoxyBond’s protection is based primarily on formulation and abuse-deterrence intellectual property rather than on new chemical entity protection for oxycodone. The active ingredient is an established molecule with extensive generic competition.
Relevant protection can include:
- Patents covering the abuse-deterrent matrix.
- Patents covering excipient combinations.
- Patents covering resistance to crushing, grinding, heating, or extraction.
- Manufacturing-process patents.
- Method-of-use patents, where listed.
- Regulatory exclusivity associated with the approved NDA.
The FDA Orange Book is the controlling source for patents listed against NDA 209777 and for any associated pediatric exclusivity or patent certifications. [6] Patent scope and enforceability must be assessed patent by patent. A formulation patent generally does not prevent competitors from selling ordinary oxycodone tablets that do not practice the claimed formulation.
A key commercial distinction is the difference between product protection and market protection. RoxyBond may retain formulation claims even while generic oxycodone remains widely available. That structure limits the ability of patents to create a broad monopoly over immediate-release oxycodone.
When does RoxyBond lose exclusivity?
RoxyBond’s practical exclusivity depends on several dates rather than one universal expiration date:
- FDA approval date: 2017.
- New chemical entity exclusivity: not applicable because oxycodone was previously approved.
- Five-year NCE exclusivity: not available.
- Three-year clinical-investigation exclusivity: may apply to qualifying approval-related investigations, subject to FDA determination.
- Patent exclusivity: depends on the listed patents and their adjusted expiration dates.
- Regulatory exclusivity: depends on the NDA’s specific FDA exclusivity listings.
The product’s commercial protection is weaker than that of a new molecular entity because oxycodone itself is old and generic. The principal barrier is formulation-specific intellectual property, not ingredient-level exclusivity.
Are generic manufacturers challenging RoxyBond?
No RoxyBond-specific Paragraph IV challenge is identified in the cited public sources. That does not mean that future challenges are impossible. A generic applicant could pursue several strategies:
- File an ANDA for ordinary oxycodone immediate-release tablets without seeking an abuse-deterrent formulation.
- Challenge listed RoxyBond patents under Paragraph IV.
- Develop a competing abuse-deterrent formulation.
- Wait for relevant patents or exclusivity to expire.
- Argue that particular claims are invalid, not infringed, or unenforceable.
An ANDA for ordinary oxycodone would not necessarily be an equivalent substitute for RoxyBond’s abuse-deterrent formulation. The regulatory and commercial effect would depend on the FDA’s therapeutic-equivalence rating and the scope of the relevant formulation claims.
What patent litigation affects RoxyBond?
RoxyBond’s principal litigation risk is generic patent litigation involving its abuse-deterrent formulation. Publicly reported opioid litigation has largely focused on marketing practices, distribution controls, public nuisance theories, and governmental claims rather than on RoxyBond-specific patent disputes.
The absence of a prominent public patent case does not remove litigation risk. A Paragraph IV filing would require Collegium or the relevant patent owner to decide whether to sue within the statutory window. Potential outcomes include:
- A 30-month stay of ANDA approval.
- Early settlement with a licensed entry date.
- Patent invalidation.
- Non-infringement judgment.
- Generic entry after patent expiry.
- Launch at risk before final patent resolution.
How strong is the RoxyBond patent estate?
RoxyBond’s patent estate is strategically narrower than a new chemical entity estate because competitors can market non-abuse-deterrent oxycodone. Its strength depends on four factors:
- Claim breadth across abuse-deterrent mechanisms.
- Validity of formulation and manufacturing claims.
- Ability to prove infringement through publicly observable product characteristics.
- Commercial willingness of payers to distinguish RoxyBond from generic oxycodone.
Formulation patents can be valuable when they cover a technically difficult and commercially necessary product attribute. Their value is lower when physicians and payers treat the product as interchangeable with a low-cost generic.
RoxyBond also faces a design-around risk. A competitor may avoid asserted claims by using different excipients, manufacturing conditions, or abuse-deterrent mechanisms while preserving an immediate-release oxycodone indication.
What generic entry risks exist for RoxyBond?
The main generic-entry scenarios are:
| Scenario |
Timing effect |
Commercial consequence |
| No abuse-deterrent generic enters |
Preserves niche differentiation |
RoxyBond remains a premium option |
| Ordinary oxycodone generic gains broader formulary preference |
Immediate pressure |
Lower utilization and price resistance |
| Paragraph IV challenge succeeds |
Accelerated erosion |
Potential sharp loss of branded share |
| Competing abuse-deterrent product launches |
Moderate pressure |
Formulary competition and rebate escalation |
| Patent settlement permits later entry |
Delayed erosion |
Predictable decline after agreed date |
| Manufacturing interruption |
Immediate supply risk |
Substitution and loss of prescriber confidence |
The greatest near-term threat is not necessarily an AB-rated abuse-deterrent generic. It is payer and prescriber substitution to inexpensive immediate-release oxycodone.
How does RoxyBond compare with Xtampza ER and other abuse-deterrent opioids?
RoxyBond and Xtampza ER both use abuse-deterrent technology, but they address different clinical and commercial needs.
| Product |
Ingredient |
Release profile |
Commercial distinction |
| RoxyBond |
Oxycodone HCl |
Immediate release |
Abuse-deterrent IR oxycodone |
| Xtampza ER |
Oxycodone |
Extended release |
Abuse-deterrent ER oxycodone |
| OxyContin |
Oxycodone HCl |
Extended release |
Branded ER oxycodone with abuse-deterrent formulation |
| Generic oxycodone IR |
Oxycodone HCl |
Immediate release |
Low-cost standard formulation |
| Nucynta |
Tapentadol |
Immediate release and extended release |
Different active ingredient and mechanism |
| Belbuca |
Buprenorphine |
Buccal film |
Different opioid delivery system |
Xtampza ER has a broader commercial role within Collegium because extended-release products generally carry higher unit economics and more differentiated formulation technology. RoxyBond is more exposed to generic substitution because immediate-release oxycodone is widely available at low cost.
What licensing deals affect RoxyBond?
RoxyBond originated from Inspirion’s formulation platform and entered Collegium’s commercial portfolio through a rights transaction. Public disclosures identify Collegium as the commercial owner, but they do not provide a complete, current product-level schedule of royalties, milestones, manufacturing payments, or transfer-pricing obligations.
Those contractual terms matter for profitability. A branded product with modest sales can remain economically useful if manufacturing costs are low and royalty obligations are limited. Conversely, licensing payments, minimum purchase commitments, or specialized production requirements can reduce contribution margin.
What is the long-term commercial outlook for RoxyBond?
RoxyBond is best characterized as a mature, niche branded opioid with defensible formulation differentiation but limited market expansion potential. Its base-case trajectory is stable-to-declining revenue, shaped by the overall contraction in opioid prescribing and persistent generic price competition.
Potential upside is limited but identifiable:
- Greater payer recognition of abuse-deterrent formulations.
- Institutional procurement policies favoring abuse-deterrent opioids.
- Supply disruption among competing branded products.
- Successful contracting with government or specialty channels.
- Increased demand for immediate-release products with manipulation resistance.
Downside risks are more immediate:
- Generic substitution.
- Formulary exclusion.
- Regulatory restrictions.
- Opioid litigation costs.
- Manufacturing interruption.
- Patent invalidation or design-around.
- Continued reduction in opioid prescribing.
Key Takeaways
- RoxyBond is an FDA-approved abuse-deterrent immediate-release oxycodone product launched in 2017.
- Collegium Pharmaceutical is the principal commercial company associated with the product.
- RoxyBond has no disclosed standalone revenue series, so its financial trajectory cannot be measured independently from Collegium’s public filings.
- Its commercial value is niche and portfolio-based rather than driven by broad market growth.
- Generic oxycodone is the main competitive threat, even when it does not duplicate RoxyBond’s abuse-deterrent formulation.
- RoxyBond’s protection is formulation-focused, not ingredient-focused.
- No RoxyBond-specific Paragraph IV litigation is identified in the cited public sources.
- The most likely financial outlook is stable-to-declining sales unless formulary policy gives greater value to abuse-deterrent immediate-release opioids.
FAQs
Is RoxyBond stronger than regular oxycodone?
RoxyBond contains oxycodone hydrochloride, so its analgesic strength is determined by the dosage and opioid tolerance of the patient. Its distinguishing attribute is abuse-deterrent formulation technology, not a fundamentally stronger active ingredient.
Can pharmacies automatically substitute generic oxycodone for RoxyBond?
Automatic substitution depends on the FDA therapeutic-equivalence designation, state pharmacy law, payer policy, and the specific product. Ordinary generic oxycodone does not necessarily duplicate RoxyBond’s abuse-deterrent formulation.
Does RoxyBond have a new-drug patent on oxycodone?
No. Oxycodone is an established active ingredient. RoxyBond’s intellectual-property position is based primarily on formulation, manufacturing, and abuse-deterrence claims.
Is RoxyBond included in Collegium’s reported product revenue?
Collegium reports consolidated product revenue but does not consistently publish a separate annual RoxyBond revenue figure. RoxyBond is therefore part of the company’s portfolio economics rather than a separately valued public reporting segment.
Could an abuse-deterrent generic replace RoxyBond?
Yes. A competitor could seek approval for an abuse-deterrent oxycodone formulation or challenge RoxyBond patents. Commercial substitution would depend on FDA approval, therapeutic-equivalence treatment, patent outcomes, payer coverage, and pricing.
References
- U.S. Food and Drug Administration. (2017). RoxyBond (oxycodone hydrochloride) tablets, prescribing information.
- U.S. Food and Drug Administration. (2015). Abuse-deterrent opioid analgesics: Evaluation and labeling guidance for industry.
- U.S. Food and Drug Administration. (2022). Opioid analgesic Risk Evaluation and Mitigation Strategy.
- Centers for Disease Control and Prevention. (2024). U.S. opioid dispensing rate maps and prescribing data.
- Collegium Pharmaceutical, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
